<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829907</url>
  </required_header>
  <id_info>
    <org_study_id>3098005</org_study_id>
    <nct_id>NCT00829907</nct_id>
  </id_info>
  <brief_title>A PET Study With ORM-12741</brief_title>
  <official_title>Effect of ORM-12741 on Receptor Occupancy Studied by Positron Emission Tomography; an Open, Single Dose, Dose Ranging Study in Healthy Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of ORM-12741 on receptor occupancy by&#xD;
      positron emission tomography with different doses and plasma concentrations. The&#xD;
      pharmacokinetic profile and safety will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Receptor occupancy</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables including peak concentration in plasma, time to peak concentration, area under the plasma concentration-time curve</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety variables including blood pressure, heart rate, electrocardiogram, physical examination, laboratory safety variables (haematology, chemistry, serology, urinanalysis) and adverse events.</measure>
    <time_frame>During the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orm-12741</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORM-12741</intervention_name>
    <description>Single dose as a capsule, oral administration</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good general health ascertained by detailed medical history and physical examination&#xD;
&#xD;
          -  Males between 18 and 45 years&#xD;
&#xD;
          -  Body mass index (BMI; weight/height2) between 18-30 kg/m2&#xD;
&#xD;
          -  Weight 55-95 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of clinically significant cardiovascular, renal, hepatic, haematological,&#xD;
             gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or&#xD;
             psychiatric disease as judged by the investigator&#xD;
&#xD;
          -  Any condition requiring regular concomitant medication including herbal products or&#xD;
             likely to need any concomitant medication during the study&#xD;
&#xD;
          -  Regular consumption of more than 21 units of alcohol per week (1 unit = 4 cl spirits,&#xD;
             about 13 g of alcohol).&#xD;
&#xD;
          -  Current use of nicotine-containing products more than 5 cigarettes or equivalent/day&#xD;
&#xD;
          -  Inability to refrain from using nicotine-containing products during the stay at the&#xD;
             study centre&#xD;
&#xD;
          -  Inability to refrain from consuming caffeine-containing beverages during the stay at&#xD;
             the study centre e.g. propensity for headache when refraining from caffeine-containing&#xD;
             beverages&#xD;
&#xD;
          -  Blood donation or loss of significant amount of blood within 3 months prior to the&#xD;
             screening visit&#xD;
&#xD;
          -  Abnormal 12-lead electrocardiogram (ECG) finding of clinical relevance&#xD;
&#xD;
          -  Any abnormal value of laboratory, vital signs, or physical examination, which may in&#xD;
             the opinion of the investigator interfere with the interpretation of the test results&#xD;
             or cause a health risk for the subject if he takes part into the study&#xD;
&#xD;
          -  Anatomical abnormality in brain MRI which may in the opinion of the investigator&#xD;
             interfere with the interpretation of the PET results&#xD;
&#xD;
          -  Participation in another clinical drug study within 3 months prior to the start of&#xD;
             this study or earlier participation in a clinical study with ORM-12741&#xD;
&#xD;
          -  Participation in a prior PET study&#xD;
&#xD;
          -  Any contraindication to MRI of the brain&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juha Rinne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku PET Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku PET centre</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <last_update_submitted>November 23, 2009</last_update_submitted>
  <last_update_submitted_qc>November 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Orion Corporation, Orion Pharma (Aila Holopainen, Clinical Study Director)</name_title>
    <organization>Clinical study management</organization>
  </responsible_party>
  <keyword>Healthy volunteer study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

